About: laronidase

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: laronidase Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

pharmaceutical drug

Attributes	Values
rdf:type	Item
description	composto chimico (it) composé chimique (fr) תרכובת (he) chemische Verbindung (de) pharmaceutical drug (en) քիմիական միացություն (hy) chemická sloučenina (cs) chemische verbinding (nl) kemia kombinaĵo (eo) związek chemiczny (pl) component quimic (oc) compost químic (ca) composto químico (gl) composto químico (pt) composto químico (pt-br) compuesto quimico (an) compuestu químicu (ast) compus chimic (ro) kemiallinen yhdiste (fi) kjemisk forbindelse (nb) kjemisk sambinding (nn) konposatu kimiko (eu) مركب كيميائي (ar) کیٖمیٲیی مُرَکَب (ks) রাসায়নিক যৌগ (bn) compuesto químico (es)
rdfs:label	laronidase (en) laronidase (fr) laronidase (nn)
skos:prefLabel	laronidase (en) laronidase (fr) laronidase (nn)
name	laronidase (en) laronidase (fr) laronidase (nn)
World Health Organ...-proprietary name	wds:Q20801774-3F7DB5AC-B1F6-4EEF-97F5-9A1D7E2F3C7D
ATC code	wds:Q20801774-130FFBA3-C317-4AB6-8064-DEB15A7A6ED6
World Health Organ...-proprietary name	Laronidase (en)
ATC code	A16AB05
has characteristic	wds:Q20801774-F4AB32A1-8B7A-4C32-A81F-AFE192255434
instance of	wds:Q20801774-979C1799-32D6-4503-BE3C-BB24B128A154
has characteristic	biopharmaceutical
instance of	type of chemical entity
subclass of	wds:Q20801774-C79BEFA8-E64D-4062-BAFC-43E0984EB003
subclass of	alpha-glucosidase
has use	wds:Q20801774-DE257916-2680-4CE6-A096-9EB8AA1A787A
has use	medication
NDF-RT ID	wds:Q20801774-0CD77CD6-6A87-4836-9271-B9AB50B9EE1B
CAS Registry Number	wds:Q20801774-232A36DD-959C-4166-BE4C-E1A8CB403803
RxNorm ID	wds:Q20801774-92AEC116-1565-4080-AC82-86D7874E01AD
UNII	wds:Q20801774-B1CF9CCD-4F6B-4C0C-A6C6-80A77B7FF409
DrugBank ID	wds:Q20801774-EA5E6953-47BF-4592-866E-13D51EE2380B
NDF-RT ID	http://purl.bioontology.org/ontology/NDFRT/N0000148807
NDF-RT ID	N0000148807
CAS Registry Number	210589-09-6
RxNorm ID	392509
UNII	WP58SVM6R4
DrugBank ID	00090
medical condition treated	wds:Q20801774-85B65650-6E8A-4A79-BABF-3A2B6F1322E5
ChEMBL ID	wds:Q20801774-056EA5C2-2482-494F-9FB4-6596352A4328
ChEMBL ID	http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL1201595
medical condition treated	mucopolysaccharidosis I
ChEMBL ID	CHEMBL1201595
skos:altLabel	Alpha-L-iduronidase precursor (en)
active ingredient in	wds:Q20801774-40A4965F-38BA-4870-97A8-FBB1917E7387
active ingredient in	Aldurazyme
legal status (medicine)	wds:Q20801774-8ED0CDA8-57A2-4F90-83E4-AFFF837A680C
legal status (medicine)	boxed warning
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q20801774
is drug or therapy used for treatment of	mucopolysaccharidosis I
is drug or therapy used for treatment of	wds:Q1906054-1877D73C-A6D8-4D0A-80EF-D170A6988B2C
is main subject of	Enzyme replacement therapy with laronidase (Aldurazyme ® ) for treating mucopolysaccharidosis type I Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Laronidase treatment of mucopolysaccharidosis I. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships Uptake of a recombinant human alpha-L-iduronidase (laronidase) by cultured fibroblasts and osteoblasts Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation. Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I. Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I (Hurler-Scheie) treated with enzyme replacement therapy (laronidase, Aldurazyme) Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme) Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. therapy Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type I Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I Laronidase replacement therapy improves myocardial function in mucopolysaccharidosis I. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software